$9.44
5.60% yesterday
NYSE, Apr 10, 10:00 pm CET
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Zymeworks Inc. Stock price

$9.44
-1.66 14.96% 1M
-3.40 26.48% 6M
-5.20 35.52% YTD
+0.35 3.85% 1Y
+3.36 55.26% 3Y
-28.34 75.01% 5Y
-3.56 27.38% 10Y
NYSE, Closing price Thu, Apr 10 2025
-0.56 5.60%
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Key metrics

Market capitalization $662.19m
Enterprise Value $454.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.96
P/S ratio (TTM) P/S ratio 8.68
P/B ratio (TTM) P/B ratio 1.94
Revenue growth (TTM) Revenue growth 0.38%
Revenue (TTM) Revenue $76.30m
EBIT (operating result TTM) EBIT $-119.82m
Free Cash Flow (TTM) Free Cash Flow $-109.75m
Cash position $225.78m
EPS (TTM) EPS $-1.62
P/E forward negative
P/S forward 7.01
EV/Sales forward 4.82
Short interest 10.10%
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Zymeworks Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Zymeworks Inc. forecast:

Buy
78%
Hold
22%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
76 76
0% 0%
100%
- Direct Costs 11 11
35% 35%
15%
65 65
11% 11%
85%
- Selling and Administrative Expenses 39 39
9% 9%
51%
- Research and Development Expense 135 135
6% 6%
176%
-109 -109
10% 10%
-142%
- Depreciation and Amortization 11 11
35% 35%
15%
EBIT (Operating Income) EBIT -120 -120
13% 13%
-157%
Net Profit -123 -123
3% 3%
-161%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Neutral
24/7 Wall Street
16 days ago
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Neutral
GlobeNewsWire
16 days ago
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upco...
Neutral
GlobeNewsWire
17 days ago
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 286
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today